Registry-listed formulations

tezosentan · mesh:C120582

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 2 completed trials

    Completion Rate
    50%(2/4)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)
    Terminated
    2(50%)

    Phase Distribution

    Phase 3
    3
    75%
    Phase 2
    1
    25%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    3

    Late Stage

    Phase Distribution4 total trials
    Phase 2Efficacy & side effects
    1(25.0%)
    Phase 3Large-scale testing
    3(75.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    2 of 4 finished

    Non-Completion Rate

    50.0%

    2 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(2)
    Terminated(2)

    Detailed Status

    Terminated2
    Completed2

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (25.0%)
    Phase 33 (75.0%)

    Trials by Status

    terminated250%
    completed250%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_3

    Tezosentan in the Treatment of Acute Heart Failure

    NCT00524433
    completedphase_3

    Tezosentan in Acute Heart Failure

    NCT00525707
    terminatedphase_3

    Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

    NCT00458276
    terminatedphase_2

    Tezosentan in Pulmonary Arterial Hypertension

    NCT01077297

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00524433Phase 3

    Tezosentan in the Treatment of Acute Heart Failure

    Completed
    NCT00525707Phase 3

    Tezosentan in Acute Heart Failure

    Completed
    NCT00458276Phase 3

    Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

    Terminated
    NCT01077297Phase 2

    Tezosentan in Pulmonary Arterial Hypertension

    Terminated

    All 4 trials loaded

    Drug Details

    Intervention Type
    Drug
    Molecule Type
    Small molecule
    Total Trials
    4

    External References

    ChEMBL
    CHEMBL61780

    Names & Codes

    Research Codes

    ACT-050089RO 61-0612